Effect of tibolone and raloxifene on serum markers of apoptosis in postmenopausal women

References

• Huang KE, Baber R. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric 2010;13:317–27
   PubMed Web of Science ®Google Scholar
• Kenemans P. Tibolone: how does its mechanism of action translate into clinical effects. Maturitas 2004;48(Suppl 1):S1–3
   PubMedGoogle Scholar
• Campisi R, Marengo FD. Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator. Cardiovasc Drug Rev 2007;25:132–45
   PubMed Web of Science ®Google Scholar
• Gompel A, Chaouat M, Jacob D, Perrot JY, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351–9
   PubMed Web of Science ®Google Scholar
• Christodoulakos G, Lambrinoudaki I, Panoulis C, Rizos D, Coutoukos J, Creatsas G. Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women. Fertil Steril 2003;79:455–6
   PubMed Web of Science ®Google Scholar
• Zhu F, Wang Q, Guo C, . IL-17 induces apoptosis of vascular endothelial cells – a potential mechanism for human acute coronary syndrome. Clin Immunol 2011;141:152
   PubMed Web of Science ®Google Scholar
• Cangiano E, Marchesini J, Campo G, . ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am J Cardiovasc Drugs 2011;11:189–98
   PubMed Web of Science ®Google Scholar
• Ko YC, Chang CL, Chien HF, Wu CH, Lin LI. Resveratrol enhances the expression of death receptor Fas/CD95 and induces differentiation and apoptosis in anaplastic large-cell lymphoma cells. Cancer Lett 2011;309:46–53
   PubMed Web of Science ®Google Scholar
• Okazaki S, Ishikawa T, Iida S, . Clinical significance of UNC5B expression in colorectal cancer. Int J Oncol 2012;40:209–16
   PubMed Web of Science ®Google Scholar
• Havasi A, Borkan SC. Apoptosis and acute kidney injury. Kidney Int 2011;80:29–40
   PubMed Web of Science ®Google Scholar
• Song RX, Santen RJ. Apoptotic action of estrogen. Apoptosis 2003;8:55–60
   PubMed Web of Science ®Google Scholar
• Karaflou M, Lambrinoudaki I, Christodoulakos G. Apoptosis in atherosclerosis: a mini-review. Mini Rev Med Chem 2008;8: 912–18
   PubMed Web of Science ®Google Scholar
• Masse M, Hebert MJ, Troyanov S, Vigneault N, Sirois I, Madore F. Soluble Fas is a marker of peripheral arterial occlusive disease in haemodialysis patients. Nephrol Dial Transplant 2002;17:485–91
   PubMed Web of Science ®Google Scholar
• Hebert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, Madore F. Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis 2001;38:1271–6
   PubMed Web of Science ®Google Scholar
• Littlewood TD, Bennett MR. Apoptotic cell death in atherosclerosis. Curr Opin Lipidol 2003;14:469–75
   PubMed Web of Science ®Google Scholar
• Seli E, Guzeloglu-Kayisli O, Cakmak H, Kayisli UA, Selam B, Arici A. Estradiol increases apoptosis in human coronary artery endothelial cells by up-regulating Fas and Fas ligand expression. J Clin Endocrinol Metab 2006;91:4995–5001
   PubMed Web of Science ®Google Scholar
• Nagata S. Apoptosis by death factor. Cell 1997;88:355–65
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305–8
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169–78
   PubMed Web of Science ®Google Scholar
• Kim WU, Min SY, Hwang SH, Yoo SA, Kim KJ, Cho CS. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clin Exp Immunol 2010;161:453–8
   PubMed Web of Science ®Google Scholar
• Okura T, Watanabe S, Jiang Y, . Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 2002;20:895–8
   PubMed Web of Science ®Google Scholar
• Karaflou M, Kaparos G, Rizos D, Creatsa M, Christodoulakos G, Lambrinoudaki I. Estrogen plus progestin treatment: effect of different progestin components on serum markers of apoptosis in healthy postmenopausal women. Fertil Steril 2010;94:2399–401
   PubMed Web of Science ®Google Scholar
• Tanaka M, Suda T, Haze K, . Fas ligand in human serum. Nat Med 1996;2:317–22
   PubMed Web of Science ®Google Scholar
• Kavathia N, Jain A, Walston J, Beamer BA, Fedarko NS. Serum markers of apoptosis decrease with age and cancer stage. Aging (Albany NY) 2009;1:652–63
   PubMedGoogle Scholar
• Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996;156:4622–30
   PubMed Web of Science ®Google Scholar
• Kim JM, Kim JS, Jung HC, Song IS, Kim CY. Apoptosis of human gastric epithelial cells via caspase-3 activation in response to Helicobacter pylori infection: possible involvement of neutrophils through tumor necrosis factor alpha and soluble Fas ligands. Scand J Gastroenterol 2000;35:40–8
   PubMed Web of Science ®Google Scholar
• Mogi M, Fukuo K, Yang J, Suhara T, Ogihara T. Hypoxia stimulates release of the soluble form of fas ligand that inhibits endothelial cell apoptosis. Lab Invest 2001;81:177–84
   PubMed Web of Science ®Google Scholar
• Goldstein JC, Munoz-Pinedo C, Ricci JE, . Cytochrome c is released in a single step during apoptosis. Cell Death Differ 2005;12:453–62
   PubMed Web of Science ®Google Scholar
• Hodis HN. Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart. Cleve Clin J Med 2008;75(Suppl 4):S3–12
   PubMedGoogle Scholar
• Bayir H, Fadeel B, Palladino MJ, . Apoptotic interactions of cytochrome c: redox flirting with anionic phospholipids within and outside of mitochondria. Biochim Biophys Acta 2006;1757: 648–59
   Google Scholar
• Jemmerson R, LaPlante B, Treeful A. Release of intact, monomeric cytochrome c from apoptotic and necrotic cells. Cell Death Differ 2002;9:538–48
   PubMed Web of Science ®Google Scholar
• Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother 2008;57:759–75
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martin-Ventura JL, de Teresa E, . Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol 2007;27:168–74
   PubMed Web of Science ®Google Scholar
• de Claro RA, Zhu X, Tang J, . Hematopoietic Fas deficiency does not affect experimental atherosclerotic lesion formation despite inducing a proatherogenic state. Am J Pathol 2011;178:2931–7
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martin-Ventura JL, Tunon J, Garcia-Camarero T, Berrazueta JR, Egido J. Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease: a novel biomarker of endothelial function? Atherosclerosis 2008;201:407–12
   PubMed Web of Science ®Google Scholar
• Boos CJ, Balakrishnan B, Blann AD, Lip GY. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemost 2008;6:1841–50
   PubMed Web of Science ®Google Scholar
• Geng J, Fan J, Jiang HW, . Elevated serum soluble Fas ligand is a promising marker of testicular toxicity induced by epirubicin in rats. Toxicol Lett 2009;186:96–103
   PubMed Web of Science ®Google Scholar
• Maeda K, Ohara Y, Hashimoto M, Ohguro H. Analysis of sFas IL-6 levels in thyroid-associated ophthalmopathy: pre- or poststeroid pulse treatment. Clin Ophthalmol 2008;2:609–12
   PubMedGoogle Scholar
• Nabipour I, Kalantarhormozi M, Assadi M, . Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism. Endocrine 2010;38:406–11
   PubMed Web of Science ®Google Scholar
• Cap J, Ceeova V, Skacha M, Rezek P, Vlcek P, Blaha M. Plasma filtration in the treatment of Graves’ ophthalmopathy: a randomized study. J Clin Apher 2010;25:209–15
   PubMed Web of Science ®Google Scholar
• Andrikoula M, Kolaitis N, Vartholomatos G, Tsatsoulis A. Serum levels of soluble fas in patients with multinodular goiter. Immunol Invest 2009;38:398–407
   PubMed Web of Science ®Google Scholar
• Niewczas MA, Ficociello LH, Johnson AC, . Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009;4:62–70
   PubMed Web of Science ®Google Scholar
• El-Agroudy AE, El-Baz A. Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients. Clin Exp Nephrol 2010;14:152–7
   PubMed Web of Science ®Google Scholar
• Goes MA, Dalboni MA, Manfredi SR, . Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease. Clin Nephrol 2010;73:7–13
   PubMed Web of Science ®Google Scholar
• Tamimi TI, Elgouhari HM, Alkhouri N, . An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011;54: 1224–9
   PubMedGoogle Scholar
• Zekri AR, Alam El-Din HM, Bahnassy AA, . Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp Hepatol 2010;9. Jan 5. Epub ahead of print
   Google Scholar
• Aguilar-Lemarroy A, Romero-Ramos JE, Olimon-Andalon V, . Apoptosis induction in Jurkat cells and sCD95 levels in women’s sera are related with the risk of developing cervical cancer. BMC Cancer 2008;8:99
   Web of Science ®Google Scholar
• Kilic A, Schuchert MJ, Luketich JD, . Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum. J Thorac Cardiovasc Surg 2008;136:199–204
   PubMed Web of Science ®Google Scholar
• Watson GA, Naran S, Zhang X, Stang MT, Queiroz de Oliveira PE, Hughes SJ. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis. Neoplasia 2011;13:198–205
   Google Scholar
• Boroumand-Noughabi S, Sima HR, Ghaffarzadehgan K, . Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer 2010;10:275
   PubMedGoogle Scholar
• Ulukaya E, Acilan C, Yilmaz M, . sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients. Cell Biochem Funct 2010;28:565–70
   PubMed Web of Science ®Google Scholar
• Christodoulakos GE, Lambrinoudaki IV, Creatsa MG, . Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. Climacteric 2008;11:155–65
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231–8
   PubMed Web of Science ®Google Scholar
• Bundred NJ, Turner LE. Postmenopausal therapy before and after breast cancer: clinical experiences. Maturitas 2004;49:S22–31
   PubMed Web of Science ®Google Scholar
• Kubista E, Planellas gomez JV, Dowsett M, . Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial. Clin Cancer Res 2007; 13:4185–90
   Web of Science ®Google Scholar
• Krum SA, Miranda-Carboni GA, Hauschka PV, . Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008;27:535–45
   PubMed Web of Science ®Google Scholar
• Nakamura T, Imai Y, Matsumoto T, . Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007;130:811–23
   PubMed Web of Science ®Google Scholar
• Yu J, Eto M, Akishita M, Okabe T, Ouchi Y. A selective estrogen receptor modulator inhibits TNF-alpha-induced apoptosis by activating ERK1/2 signaling pathway in vascular endothelial cells. Vascul Pharmacol 2009;51:21–8
   PubMed Web of Science ®Google Scholar
• Garcia-Moreno C, Catalan MP, Ortiz A, Alvarez L, De la Piedra C. Modulation of survival in osteoblasts from postmenopausal women. Bone 2004;35:170–7
   PubMed Web of Science ®Google Scholar
• Barczyk K, Kreuter M, Pryjma J, . Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer 2005;116:167–73
   PubMed Web of Science ®Google Scholar
• Adachi N, Hirota M, Hamaguchi M, Okamoto K, Watanabe K, Endo F. Serum cytochrome c level as a prognostic indicator in patients with systemic inflammatory response syndrome. Clin Chim Acta 2004;342:127–36
   PubMed Web of Science ®Google Scholar
• Hamerski MG, Bortolini MA, Da Silva ID, . Effect of tibolone on cytochrome c oxidase I, beta-2-microglobulin and vascular endothelial growth factor gene expression in the lower urinary tract of castrated rats. Clin Exp Obstet Gynecol 2006;33: 233–7
   PubMedGoogle Scholar
• de Oliveira MC, Martins-Maciel ER, Comar JF, . Tibolone impairs glucose and fatty acid metabolism and induces oxidative stress in livers from female rats. Eur J Pharmacol 2011;668:248–56
   PubMed Web of Science ®Google Scholar
• Morishima S, Shibata MA, Ohmichi M, Otsuki Y. Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells. Med Mol Morphol 2008;41:132–8
   PubMed Web of Science ®Google Scholar
• Razmara A, Sunday L, Stirone C, . Mitochondrial effects of estrogen are mediated by estrogen receptor alpha in brain endothelial cells. J Pharmacol Exp Ther 2008;325:782–90
   PubMed Web of Science ®Google Scholar
• Shirai R, Gotou R, Hirano F, Ikeda K, Inoue S. Autologous extracellular cytochrome c is an endogenous ligand for leucine-rich alpha2-glycoprotein and beta-type phospholipase A2 inhibitor. J Biol Chem 2010;285:21607–14
   PubMed Web of Science ®Google Scholar
• Cummings C, Walder J, Treeful A, Jemmerson R. Serum leucine-rich alpha-2-glycoprotein-1 binds cytochrome c and inhibits antibody detection of this apoptotic marker in enzyme-linked immunosorbent assay. Apoptosis 2006;11:1121–9
   PubMed Web of Science ®Google Scholar
• Ito Y, Nakachi K, Imai K, . Stability of frozen serum levels of insulin-like growth factor-I, insulin-like growth factor-II, insulin-like growth factor binding protein-3, transforming growth factor beta, soluble Fas, and superoxide dismutase activity for the JACC study. J Epidemiol 2005;1:67–73
   Google Scholar